Ad
Short

CoreWeave is set to acquire data center provider Core Scientific in a share swap deal worth about $9 billion. The transaction is expected to close in the fourth quarter of 2025. Core Scientific adds 1.3 gigawatts of existing power capacity, plus more than 1 gigawatt of expansion potential.

CoreWeave, which calls itself an "AI hyperscaler," specializes in cloud infrastructure for compute-intensive AI workloads. By owning its own data centers, the company aims to lower costs and reduce dependence on outside providers as competition heats up in the AI infrastructure market. In March, OpenAI invested $12 billion in CoreWeave. CoreWeave has also reportedly benefited from Microsoft scaling back its own AI data center investments.

Ad
Ad
Short

Capgemini is investing $3.3 billion to bring generative AI and so-called "agentic AI" into its clients' business operations.

The company plans to acquire WNS, a provider of digital business process services, as part of this push. "Business Process Services will be the showcase for Agentic AI," Capgemini CEO Aiman Ezzat said about the deal. WNS already delivers AI-powered process solutions to companies in eight industries, counting United Airlines and Aviva among its clients.

Capgemini and WNS say the goal is to become a leader in intelligent operations by using autonomous AI to fundamentally rethink how businesses run their core processes.

Short

Isomorphic Labs, a Deepmind spin-off focused on drug discovery, is getting ready for its first clinical trials with drugs designed using AlphaFold-based AI models.

"We're staffing up now. We're getting very close," said Colin Murdoch, President of Isomorphic Labs and Chief Business Officer at Deepmind, in an interview with Fortune.

The company wants to overhaul the traditionally slow and expensive process of drug development, with anti-cancer drugs already in the pipeline. Isomorphic Labs has signed agreements with Eli Lilly and Novartis, and in 2025 closed a USD 600 million investment round led by Thrive Capital.

Looking ahead, Isomorphic Labs has even bigger ambitions for AI in medicine. "One day we hope to be able to say— well, here's a disease, and then click a button and out pops the design for a drug to address that disease," Murdoch said.

Ad
Ad
Ad
Ad
Google News